Management

edit

Treatment of AMD varies depending on the category of the disease at the time of diagnosis. In general, treatment is aimed at slowing down the progression of AMD.[1] As of 2018, there are no treatments to reverse the effects of AMD[1]. Early-stage and intermediate-stage AMD is managed by modifying known risk factors such as smoking and atherosclerosis and making dietary modifications.[1] For intermediate-stage AMD, management also includes antioxidant and mineral supplementation.[1][2][3] Advanced-stage AMD is managed based on the presence of choroidal neovascularization (CNV): dry AMD (no CNV present) or wet AMD (CNV present).[1] No effective treatments exist for dry AMD.[1] The CNV present in wet AMD is managed with vascular endothelial growth factor (VEGF) inhibitors.[1][4][5]


Dry AMD

edit

No medical or surgical treatment is available for this condition.

Wet AMD

edit

Ranibizumab and aflibercept are approved VEGF inhibitors for the treatment of CNV in wet AMD.[4] Bevacizumab is another VEGF inhibitor that has been shown to have similar efficacy and safety as the previous two drugs, however, is not currently indicated for AMD.[5] AMD can also be treated with laser coagulation therapy.[6]

  1. ^ a b c d e f g Bishop P. Age-related macular degeneration. BMJ Best Practice. 2018.
  2. ^ Evans, Jennifer R; Lawrenson, John G (2017-07-30). "Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd000253.pub4. ISSN 1465-1858.
  3. ^ Lawrenson, John G; Evans, Jennifer R (2015-04-09). "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010015.pub3. ISSN 1465-1858.
  4. ^ a b Sarwar, Salman; Clearfield, Elizabeth; Soliman, Mohamed Kamel; Sadiq, Mohammad Ali; Baldwin, Andrew J; Hanout, Mostafa; Agarwal, Aniruddha; Sepah, Yasir J; Do, Diana V (2016-02-08). "Aflibercept for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011346.pub2. ISSN 1465-1858. PMC 5030844. PMID 26857947.{{cite journal}}: CS1 maint: PMC format (link)
  5. ^ a b Lawrenson, John G; Evans, Jennifer R (2015-04-09). "Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd010015.pub3. ISSN 1465-1858.
  6. ^ Virgili, Gianni; Bini, Alessandro (2007-07-18). "Laser photocoagulation for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004763.pub2. ISSN 1465-1858.

Comments

edit

Thanks for all of these suggestions. I think you have done a great job organizing this info and finding high quality sources in your ref list. A few notes:

  • When citing references, please place them immediately after the punctuation like this.1
  • Remember that as per WP:MEDRS we cannot add in RCTs. If you have a reference that has reviewed this RCT, you can change the sentence to: Bevacizumab and ranibizumab have/appear to have/may have (depending on the strength of the evidence) , and there are no side effects .... (once again, the use no "no/may not be/weak evidence suggests that depends on the strength of evidence you are presenting which will come from the secondary source). Cochrane reviews always state the strength of evidence.
  • See if you can add Wikilinks to a few med terms- IV could use one, unless already linked earlier in the article
  • Can you expand this sentence a little "light of a certain wavelength is then applied to the abnormal blood vessels" to explain it to readers who are not familiar with this field?
  • I see you also have a second sentence explaining the results of a RCT. All your references look like great high quality secondary sources. Please see above comment for both instances where it appears you are citing a primary study. If you have any questions please do not hesitate to let me know.

Thanks again for helping to improve the article. JenOttawa (talk) 16:17, 6 November 2018 (UTC)

You did a nice job here improving the text. Do you have a reference indicating that there are no tx options for dry AMD? JenOttawa (talk) 16:17, 6 November 2018 (UTC)